Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 76

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 76
---
 status of RSUs from October 1, 2024 through March 31, 2025:

			Number of RSU (#)

			Weighted Average Grant Date Fair Value

			Six Months Ended March 31, 2025

			Balance - September 30, 2024

			63,204

			$
			5.10

			Granted

			37,429

			2.39

			Exercised

			(2,486
			)

			5.60

			Balance - March 31, 2025

			98,147

			$
			4.06

			Six Months Ended March 31, 2024

			Balance - September 30, 2023

			33,045

			$
			5.60

			Granted

			8,651

			4.77

			Balance - March 31, 2024

			41,696

			$
			5.43

The following table summarizes information about the RSUs under the 2019 Plan outstanding and exercisable at March 31, 2025:

			Number of RSU (#) 

			Expiry Date

			Fully-vested RSUs

			98,147

			August 2033 - March 2035

All RSUs that were granted vested immediately upon the grant date. The outstanding RSUs can be converted to Common Shares by the holder at any time prior to the expiry date. There is no future unrecorded compensation expense for the RSUs.

7. Government Contributions

Reimbursement grant income for the Company’s federal grant with the Canadian government’s SIF is recorded based on the claim period of eligible costs.

In October 2023, the Company entered into a multi-year contribution agreement (the 2023 SIF Agreement) with the Canadian Government’s Strategic Innovation Fund. Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding toward (i) conducting and completing the Company’s Phase 3 clinical study of its experimental drug EB05 in critical-care patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 or other infectious agents, (ii) submitting EB05 for governmental approvals and manufacturing scale-up, following, and subject to, completing the Phase 3 study and (